The Exchange has sought clarification from Nureca Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies 1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 2.0 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked Nureca Limited to clarify discrepancies found in the financial results submitted in XBRL format for the quarter ended 30 September 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company has not yet provided its response. The issue is limited to technical/formatting differences in how the results were filed electronically, not a restatement of earnings. Investors should watch for the company's reply to understand whether any underlying numbers are affected.
This is a routine procedural query and is unlikely to impact the stock price significantly. However, delays or a non-reply could lead to further action from the exchange.